Postpartum Care	Depression: Observational Study	Depression: Observational Study
The COSI STUDY **A multi-site randomised controlled trial (RCT) to explore the clinical and cost effectiveness of the Circle of Security Intervention for mothers in perinatal mental health services.** **Sponsor**: Anna Freud National Centre for Children and Families **Inclusion Criteria** Women and other birthing parents who: Are accessing a community PMHS from one of the recruiting sites, Have a child aged 0-12 months with no severe illness or developmental disorder, Score 1.1 or more as their average score on the CORE-10 [2], Score 12 or more on the general factor of the Postnatal Bonding Questionnaire PBQ) [3], Are aged at least 18 and are willing and able to give informed consent, Are able to attend groups without being under the influence of substances. **Exclusion Criteria** Women and other birthing parents who: Do not meet the inclusion criteria, Do not have a minimum of conversational English, Have received COS-P previously, Are experiencing active psychosis. **Recruitment Pathway: Via specialist community perinatal services (CNTW)** **National Lead: Professor Peter Fonagy** **CNTW Principal Investigator : Dr Louise McCarron** **Delivery Team Lead: Emily Clare Emily.clare@cntw.nhs.uk** **Recruitment end date: 04/09/2023**	**RESTORE-LIFE** **Sponsor: LivaNova** A Global Prospective, Multi-Center, Observational post-market Study to assess short, mid and long-term Effectiveness and efficiency of VNS Therapy® as adjunctive therapy in real-world patients with difficult to treat depression. **Inclusion Criteria** Aged 18+ Primary diagnosis of chronic (>2 years) or recurrent (2 or more prior episodes) major depressive episode that has not adequately responded to antidepressant treatments Diagnosis confirmed using the Mini-International Neuropsychiatric Interview (MINI). Be able to provide informed consent Currently be receiving at least one antidepressant treatment or mood stabilizing treatment for bipolar patients; Able to comply with the clinic visits to complete all valuations **Exclusion criteria** The investigator should refer to the (local applicable) VNS Therapy Physician's Manual. Participant must satisfy all inclusion and exclusion criteria **Recruitment Pathway: Via RADS** **National Lead: Prof. Koen Demyttenaere** **PI: Dr Hamish McAllister Williams** **Research Nurse: Samantha Bulmer** **Samantha.Bulmer@cntw.nhs.uk** **Planned Rec End date: 31/07/2023**	**BDRN - Bipolar Disorder Research Network Pregnancy and Childbirth Study - On hold** **Sponsor:** Cardiff University Molecular genetic investigation of bipolar disorder and related mood disorder in nuclear families. **Inclusion Criteria** Aged 18+ Currently pregnant or Have ever experienced an episode of postpartum psychosis or any other mood episode following childbirth that required hospital or home treatment. And also: Have experienced one or more episodes of mania/hypomania at any time in the past lasting at least 4 days (who may have, or may have had, a diagnosis of bipolar I disorder, bipolar II disorder or schizoaffective disorder). **Exclusion criteria** Unable to provide informed consent. Unable to speak English fluently due to semi-structured nature of the interview Known to have a blood borne infection e.g. HIV **Recruitment Pathway: Clinician gives information leaflet to participant and gains permission to contact.** **National Lead: Dr Katherine Gordon-Smith** **PI: Dr Andrew Cairns** **Delivery Team Lead: Emily Clare** **Emily.clare@cntw.nhs.uk** **Recruitment end date: 31/12/2022**

Depression - Randomised Placebo-controlled Treatment Trial

PAX- D

Sponsor: Oxford University

Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

Inclusion Criteria:
Over 18
Moderate or major/treatment resistant depression
Taking an antidepressant medication (& willing to continue)
A lack of response to at least two antidepressants

Exclusion Criteria:
Psychosis (including psychotic depression), bipolar disorder or Parkinson's Disease
Current antipsychotic medication
Significant impulse control difficulties/ suicide or homicide risk
Medication contraindicating pramipexole metabolism including cimetidine, memantine & methyldopa
Medical conditions which contraindicate use of pramipexole
Previous course of pramipexole (>2 weeks)
Pregnant/breast-feeding/planning pregnancy or of child bearing potential & not willing to use effective contraception

Recruitment Pathway: Clinician approach via community/ inpatient/specialist services. Recruitment pathway may broaden once established.

National Lead: Prof Michael Browning
PI: Dr Stuart Watson
Delivery Team Lead: Nadia Burman
Nadia.Burman@cntw.nhs.uk

Planned recruitment end date: 31/03/2023

Bipolar -Lithium treatment Optimising Trial

R-LINK

Sponsor: l'Assistance Publique-Hôpitaux de Paris

Optimising response to Lithium treatment through personalised evaluation of individuals with bipolar 1 disorder. A major EU study which aims to identify biomarkers of response to treatment in bipolar disorder.

Inclusion Criteria
Individuals with a diagnosis of bipolar disorder type I
Aged 18-70 years old, About to start lithium treatment based on their doctor's assessment, Eligible for blood tests and magnetic resonance imaging (MRI) scans

Exclusion Criteria
Bipolar disorder type II or Schizoaffective disorder
Contraindications to MRI
Contraindications to lithium treatment
Pregnancy, breast feeding or planned pregnancy within the next 2 years
Severe risk of self-harm at present, based on clinical evaluation

Recruitment Pathway: Recruitment via prescribing clinician, identified through caseload/liaison with clinicians

National Lead: Prof Allan Young
PI: Dr David Cousins
Delivery Team Lead: Jamie Rea
Jamie.Rea@cntw.nhs.uk

Anticipated recruitment end date: 30/06/2022

Psychosis Randomised Controlled Trial

STAR (Study of Trauma And Recovery)

Sponsor: Kings College London

A Multisite Randomised Controlled Trial of Trauma-Focused CBT for psychosis for people with co-morbid post-traumatic stress disorder and psychosis, compared to Treatment as Usual.

Inclusion Criteria
Aged 18 +
Presence of schizophrenia-spectrum diagnoses / Reporting past trauma(s), occurring at least 1 month prior to assessment,
Reporting still being currently affected by at least one traumatic event / Meet DSM-5 (36) symptom criteria for PTSD diagnosis
Able and willing to engage in psychological therapy and consent to study procedures.

Exclusion Criteria
Current, primary diagnosis of substance use disorder/ Organic factors implicated in the primary aetiology of psychosis and/or PTSD/ Current (or in previous 3 months) engagement in trauma-focused therapy/ Insufficient English to provide informed consent or complete assessments without the help of an interpreter/ Currently experiencing an acute mental health crisis

Recruitment Pathway: Clinician referral, Identified through caseload screening

National Lead: Dr Emmanuelle Peters
PI: Dr Rob Dudley
Study email: STAR@cntw.nhs.uk
Delivery Team Lead: Jamie Rea Jamie.Rea@cntw.nhs.uk
Research Assistant: Rebecca Miskin

Recruitment end date: 31/07/2022

Psychosis - Observational Study	Psychosis - Randomised Controlled Trial	
IPACCT **Sponsor:** Manchester University Improving prediction of psychosis in ARMS using a clinically useful prognostic tool (IPPACT): Phase 3 observational cohort Study. To predict ARMS individuals at highest and lowest risk of psychosis using accessible, acceptable measures. **Inclusion Criteria** Aged 16+ Attending secondary care services in the NHS who meet ARMS criteria, as defined by the CAARMS (regarding intensity, frequency duration of psychotic-like experiences and functional impairment). (Age range is included in the ARMS criteria and reflects that most psychotic disorders have their onset in late adolescence early adulthood) In contact with NHS Early Intervention Services or Child and Adolescent Mental Health Services **Exclusion Criteria** History of a treated or untreated psychotic episode of one week's duration or longer Previous or current treatment with antipsychotics at dose of over 5 mf of haloperidol or equivalent for over 3 weeks **Recruitment Pathway: Service users accepted into ARMS Service unless explicit opt out** **National Lead**: **Alison Yung** **Co CI**: **Filippo Varese** **PI**: **Dr Guy Dodgson** **Delivery Team Lead: Jamie Rea** Jamie.Rea@cntw.nhs.uk **Recruitment end date: 31/12/2022**	**MUSE-FEP Managing Unusual Sensory Experiences** **Sponsor:** Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust Managing Unusual Sensory Experiences (MUSE): A feasibility trial of a targeted, psycho-education toolkit for distressing hallucinations, in people with a first episode of psychosis: MUSE FEP trial. A randomised controlled trial comparing 4-6 sessions of MUSE therapy to treatment as usual. **Inclusion Criteria** EIP patient with identified CPN as care co-ordinator Schizophrenia/schizoaffective disorder/entry criteria for an EIP service; History of auditory hallucinations for at least four weeks; Aged 16 and above; Capacity to provide informed consent; Clinically stable for the preceding 4 weeks; No major changes in antipsychotic medication in previous month **Exclusion Criteria** Hallucinations/psychosis with a known biological basis Insufficient command of English to complete the study procedures; A primary diagnosis of substance misuse/dependency; Engaged in CBT currently or within past 6 months **Recruitment Pathway: Via EIP services only** **Contact Research worker Lucy O'Grady, or trial manager Charlotte Aynsworth, via PRU@cntw.nhs.uk** **National Lead: Dr Robert Dudley** **CNTW Principal Investigator : Dr Guy Dodgson** **Recruitment end date: 30/06/2022**	

Neurodevelopmental: Register Trial	Neurodevelopmental: Questionnaire study	Autism – Observational Study
EPILEPSY LD REGISTER **Sponsor:** Cornwall Partnership NHS Foundation Trust A register for collecting/measuring outcomes of licensed Anti-Epileptic Drugs in patients with Epilepsy and Intellectual Disability and/or Pervasive Development Disorders. To ascertain the safety and impact of AEDs in PWE on individuals with ID and/or PDD with specific focus on the intensity and frequency of seizures and the side effects associated with their use and to compare these findings with data collected for a control group of PWE who do not have ID and/or PDD. **Inclusion Criteria:** Aged 18+ Diagnosis of epilepsy Prescribed a current study medication or treatment (in a live arm of the study) It is Imperative that individuals who remain/remained on the study AED or treatment for 12 months and individuals who did not remain on the study AED or treatment for 12 months are approached. **Exclusion Criteria:** None Listed **National Lead: Dr Rohit Shankar** **PI: Dr Ian McKinnon** **Delivery Team Lead: TBC. Please contact Sarah Edwards sarah.edwards@cntw.nhs.uk with any queries** **Recruitment end date: 20/11/2024**	**ClASP-ID - The Clinical Anxiety Screen for Intellectual Disabilities** **Sponsor:** Aston University The study aims to develop a clinical tool for the detection of anxiety in non-verbal people with learning disabilities. The study is recruiting parents & carers of people aged 4+ with moderate to profound learning disabilities **Inclusion Criteria:** Parents & carers of patients aged 4+ with moderate to profound learning disabilities under the care of community secondary care services. **Exclusion criteria:** Parent or carer unable to provide informed consent **Recruitment Pathway: Study invite sent to family by delivery team on behalf of clinician.** **National Lead: Dr Joanne Tarver** **PI: Dr Barry Ingham** **Delivery Team Lead: Emily Clare** Emily.clare@cntw.nhs.uk **Recruitment end date: 01/10/2022**	**RE-ASCed** A Realist Evaluation of Autism ServiCe Delivery (RE-ASCeD): Which diagnostic pathways work best, for whom, when, and at what cost? **Sponsor:** Sussex Community NHS FT **Inclusion Criteria** Child and family currently involved in the diagnostic pathway for possible Autism (parents/guardians of children already in, or just completed pathway also able to take part) All school ages (5 -16) Provides informed consent Under management of local NHS clinical care team Agrees to have clinical records accessed (data collection form to extract useful data) by research staff or research staff from NU/SCFT/KU **Exclusion criteria** Over the age of 18, outside of school age Does not provide informed consent Not under the management of NHS local care services **Recruitment Pathway: South of Tyne Children and Young People's Service's** **National Lead: Dr Ian Male** **CNTW Principal Investigator: Dr Laura Rollisson** **Delivery Team Lead: Michael Kelly michael.kelly@cntw.nhs.uk** **Recruitment end date: 31/08/2022**

Trauma	Secure Care Services	DEMENTIA Longitudinal Observational
RESTART **Sponsor:** Manchester University A mixed-method study to examine the emotional and psychological impacts of trauma and resolve barriers to trauma therapy in people with an at risk mental state **Inclusion Criteria** 16 years of age or older, Meeting ARMS criteria as defined by the CAARMS, Capacity and willingness to provide informed consent, Reported exposure to at least one potentially traumatic life events, as assessed by the Trauma and Life Events checklist (TALE) **Exclusion Criteria** Under 16 years of age, Non-English speaking or requiring an interpreter for the intervention (the assessment battery at present can only be delivered in English), Evidence of recent or past transition from ARMS status to first episode psychosis (FEP), operationally defined as meeting CAARMS transition criteria (i.e. history of a treated or untreated psychotic episode of one week's duration or longer) and/or previous or current treatment with antipsychotics at dose of over 5 mf of haloperidol or equivalent for over 3 weeks **Recruitment Pathway: Clinician to gain permission to pass contact details to delivery team** **National Lead: Dr Filippo Varese** **PI: Dr Guy Dodgson** **Delivery Team Leads: Michael Kelly** **Michael.Kelly@cntw.nhw.uk** **and Victoria Wilson Victoria.Wilson3@cntw.nhs.uk** **Recruitment end date: 01/11/2022**	**Weight management** **in adult secure care mental health settings: A mixed methods study to inform future weight management interventions**. The research will explore with adult patients, staff and carers their priorities for tackling unhealthy weight, and what would make this easier and harder to achieve. **Sponsor**: CNTW **Inclusion Criteria** Inpatient in secure mental health services with diagnosed mental health condition (for former service users – now discharged). Age 18 years and above, capacity to consent to research involvement / Staff employed at CNTW or TEWV with a role in adult secure services / Carers who udertake a formal or informal caring role for an adult inpatient/former inpatient in secure mental health services at CNTW or TEWV **Exclusion criteria** Diagnosis of an eating disorder/ likely to experience distress through addressing weight management issues/ acutely unwell and exhibiting unpredictable or violent behaviour/ Lacking capacity to consent to participate **Recruitment Pathway: Via Secure Care Services and Service User and Carer Involvement (CNTW)** **National Lead: Dr Susanna Mills** **CNTW Principal Investigator: Dr Susanna Mills** **Susanna.mills@cntw.nhs.uk** **Delivery Team Lead: Jahnese Hamilton,** **Jahnese.hamilton@cntw.nhs.uk** **Recruitment end date: 12/05/2023**	**ENLIST Study** A LEWY BODY DEMENTIA NETWORK LONGITUDINALSTUDY IN THE **UK** **Sponsor:** Kings College London **(participants can go from COGSLEEP into ENLIST)** Aims to examine clinical and biomarker predictors of the rate of cognitive decline in individuals diagnosed with dementia with Lewy bodies DLB. **Inclusion Criteria** Alzheimer's Disease and Dementia with Lewy Bodies Age 50+; Happy to have bloods; Living at home; has a carer **Exclusion criteria** Severe physical or life-threatening conditions, including cancer or other conditions with suspected survival time less than three years. Other intracranial pathology. Other physical or psychiatric conditions which may contribute to cognitive impairment; Diagnosis of possible DLB with negative dopamine transporter scan (DaT scan); >five years use of antipsychotic drugs prior to diagnosis; Contraindications to Lumbar Puncture including warfarin and anticoagulant. Study Partner who is unable to attend all study visits with the participant. **Recruitment Pathway: Recruited via case register, clinician referral and self-referral** **National Lead I: Professor Dag Aarsland** **PI: Prof John-Paul Taylor** **Delivery Team Lead: Emily Nuttall** **Emily.nuttall@cntw.nhs.uk** **Recruitment End Date: 31/03/2023**

DEMENTIA Observational Study	DEMENTIA Observational Study	DEMENTIA Observational double-blind placebo-control cross-over design study
COGSLEEP: Understanding the relationship between cognitive fluctuations, sleep and arousal in dementia with Lewy bodies **Sponsor:** CNTW NHS Foundation Trust The study Aims to better understand cognitive fluctuations in Dementia with Lewy Bodies (DLB) **Inclusion Criteria** Aged 60+ years / A diagnosis of probable DLB or AD in accordance with recognised criteria for dementia groups. Capable of providing informed consent, or if lacking capacity, having a suitable consultee (in accordance with 2005 Mental Capacity Act) / Fluent in the English language / Have remained stable on relevant medication for a period of four weeks prior to participation (DLB/AD groups) **Exclusion criteria** Metallic implants in the head/neck area, or electronic implants of any type (including pacemakers); A history of other neurological illness including, but not limited to stroke, intracerebral pathology and epilepsy; Past of present delirium; A history of excess alcohol intake; Presence of severe disease and significant physical co-morbidities; The presence of relevant visual; Impairments with the potential to interfere with attentional or visuoperceptual testing, or moderate-to-severe visual impairment secondary to glaucoma, cataract or macular degeneration.; Psychotropic and other medications which may significantly interfere with cognitive & TMS-EEG testing **Recruitment pathway: Via case register, clinician referral and self-referral** **National Lead: Prof John-Paul Taylor/ Dr. Greg Elder** **PI: Dr Kirstie Anderson** **Delivery Team Lead: Emily Nuttall** **Emily.nuttall@cntw.nhs.uk** **Recruitment End Date: 31/08/2022**	**DETERMIND: DETERMinants of quality of life, care and costs, and consequences of INequalities in people with Dementia and their carers** **Sponsor:** University of Sussex Longitudinal observational study to explore and understand inequalities in dementia care and what drives good and bad quality of life, outcomes and costs for people with dementia and their carers following diagnosis via interviews. **Inclusion Criteria:** All those with a clinical diagnosis of any form of dementia (to be consented in and activity undertaken within 6 months of diagnosis). **Exclusion criteria:** People with dementia who lack capacity will be excluded if we are unable to identify an appropriate personal or nominated consultee. **Recruitment pathway: Via case register, clinician referral and self-referral** **National Lead: Prof Sube Banerjee** **Local PI: Prof John-Paul Taylor** **Delivery Team Lead: Emily Nuttall** **Emily.nuttall@cntw.nhs.uk** **Recruitment end date: No set date- until recruitment target is met.**	**CREED Cholinergic ResponsE in Early lewy body Disease** **Sponsor:** The Newcastle upon Tyne Hospitals Aims to find the best way of predicting response to treatment for a cognitive impairment in DLB disease or PD dementia, identify who will benefit the most from treatment with a cholinesterase inhibitor. **Inclusion Criteria** Aged 60+ years / Prodromal Dementia with Lewy Bodies, dementia with Lewy Bodies, Parkinson's Disease Dementia, Parkinson's Disease with MCI; Need an informant 2x weekly; Living in own home; MOCA <26; Cholinesterase inhibitor naïve 3months prior to study (Memantine allowed) **Main Exclusion criteria** History of significant cerebrovascular disease; neurological diseases which may cause cognitive / major depression; Physical co-morbidities; cognitive enhancing medications (e.g. cholinesterase inhibitors); High dose benzodiazepines, antipsychotics or anticonvulsants; anticholinergics with significant central effects; inability to lie flat for 30 minutes, claustrophobia; Severe kidney disease; History of deep brain stimulation; Severe parkinsonism. Hypersensitivity to donepezil or piperidine derivatives. **Recruitment pathway: Recruited via case register or clinician referral** **National Lead: Prof John-Paul Taylor** **PI: Dr Alison Yarnall** **Delivery Team Lead: Victoria Hetherington** **Victoria.hetherington@cntw.nhs.uk** **Recruitment End Date: 31/12/2022**

Dementia – Questionnaire Study	Dementia - randomised double-blind placebo-controlled	HUNTINGTON'S DISEASE Longitudinal Observational
SMARTPHONES AND DEMENTIA STUDY Assistive Technology in Dementia: exploring the views and experiences of patients and their carers of smartphones - a national survey **Sponsor:** CNTW NHS Foundation Trust To undertake a national survey of people with dementia and their carers to explore their experiences and opinions relating to the use of assistive technology – specifically smartphones in dementia. **Inclusion Criteria** Anyone over the age of 18 years who has dementia or is caregiver of someone with dementia. **Exclusion Criteria** Over 18 years of age We are only approaching people who have identified themselves as either having a dementia or being carer for someone with dementia **Recruitment Pathway: only via Join Dementia Research website.** https://www.joindementiaresearch.nihr.ac.uk/ **National Lead:** **PI: Dr Robert Barber** **Delivery Team Lead: Victoria Hetherington** Victoria.hetherington@cntw.nhs.uk **Recruitment End Date: 11/11/2022**	**EVOKE/EVOKE+** A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease: **Sponsor:** Novo Nordisk A/S NB: Both the EVOKE and EVOKE+ studies are identical apart from the EVOKE+ study allowing a percentage of participants to have some degree of vascular changes on neuroimaging/vascular PMH. **Inclusion Criteria** Aged 55-85 years MCI or mild AD MMSE ≥22 Amyloid positivity established with either amyloid PET or CSF Aβ1-42 (conducted at screening). If on an acetylcholinesterase inhibitor or memantine the dose must have been stable for at least 3 months prior to screening. **Main Exclusion Criteria** Evidence of significant cerebral vascular disease on MRI Evidence of clinically relevant or unstable psychiatric disorder, Type 1 diabetes or unstable type 2, Some prohibited meds (assessed at screening), Contraindications to MRI **Recruitment Pathway: Direct referrals from clinicians / research registers** **National Lead: Naji Tabet** **PI: Dr Andrew Byrne** **Delivery Team Lead: Victoria Hetherington** Victoria.hetherington@cntw.nhs.uk **Recruitment End Date: 30/05/2022 – extension pending**	**ENROLL-HD** **Sponsor:** CHDI Foundation A multi-centre, multi-national, prospective observational study of Huntington's Disease **Inclusion Criteria** Informed consent from potential participant or legal representative is a pre-requisite for study participation. Individuals eligible for Enroll-HD will be in two major categories: **Carriers**: consists of individuals who carry the HD gene expansion mutation, whether they are currently experiencing any symptoms or not. **Controls:** Individuals who do not carry the HD gene expansion mutation; Genotype unknown- a first or second degree relative, Genotype Negative: A 1st or 2nd degree relative, related by blood to a carrier, who has had testing for HD and known not to carry HD expansion mutation or **Family Control**: Family members or individuals not related by blood to carriers **Exclusion Criteria** Individuals who do not meet inclusion criteria. Individuals with chronic movement disorders in the context of a negative test for the HD expansion mutation; those individuals with a history of or concurrent major central nervous system disorder will be excluded (e.g. stroke, Parkinson disease, Multiple Sclerosis, etc.) **Recruitment Pathway: Referral from Huntington Disease Consultants, nurses, support group and genetics clinic.** **National Lead: Prof Anne Rosser** **PI: Dr Suresh Komati** **Delivery Team Lead: Sarah Edwards** Sarah.Edwards@cntw.nhs.uk **Recruitment End Date: 31/12/2031**

Neurodegeneration Case Register

To facilitate recruitment to studies we have a Case Register for people with all types of **dementia, mild cognitive impairment, Parkinson's disease, progressive supranuclear palsy and multiple system atrophy**. The Case Register holds information about patients interested in research. Members of the Case Register can be selected for suitable studies and asked if they would like to take part. Patients throughout the region should have opportunities to take part in clinical research. For clinicians, referring to the Case Register can be a step on the way to research activity.

Send the contact details of patients you have discussed research with to us.
Either write, copy us in to a clinic letter, telephone, or email. We will then process these referrals.

How to refer patients

Please contact us at
Clinical Research Network
North East and North Cumbria Dementias and neurodegeneration (DeNDRoN),
St Nicholas Hospital
Jubilee Road, Gosforth
Newcastle upon Tyne, NE3 3XT

Copy us into a clinic letter **Phone:** 0191 246 7388 and leave a message or **Email:** dendron@cntw.nhs.uk

Data protection and confidentiality

- All data is stored securely on a CNTW Server
- The database is used by approved Network and CNTW staff
- Patient information is only released with the patient's agreement.
- Patients are free to withdraw from the Case Register at any time; we remove their details from the database

For more information on the MH Studies, please contact: Email: Researchdelivery@cntw.nhs.uk

South locality - Nadia Burman nadia.burman@cntw.nhs.uk (07971030758) & Michael Kelly Michael.Kelly@cntw.nhs.uk (07970993197)

Central Locality - (Newcastle and Gateshead) Jamie Rea jamie.rea@cntw.nhs.uk (0797 0993189) or Victoria Wilson victoria.wilson3@cntw.nhs.uk (07974594910)

North Locality - Emily Clare emily.clare@cntw.nhs.uk (07970993186) or Jahnese Hamilton Jahnese.Hamilton@cntw.nhs.uk (07584589669)

NIHR Portfolio Research Delivery Team (Mental Health), Wolfson Research Centre, C.A.V. NE4 5PL, Tel. 0191 208 1356 and leave a message

Updated 06/05/2022